Biotransformations of Anticancer Ruthenium(III) Complexes: An X-Ray Absorption Spectroscopic Study
作者:Aviva Levina、Jade B. Aitken、Yee Yen Gwee、Zhi Jun Lim、Mimi Liu、Anannya Mitra Singharay、Pok Fai Wong、Peter A. Lay
DOI:10.1002/chem.201203127
日期:2013.3.11
including aqueous buffers, protein solutions or gels (e.g, albumin, transferrin and collagen), undiluted blood serum, cell‐culture medium and human liver (HepG2) cancer cells, were studied by Ru K‐edge X‐ray absorption spectroscopy (XAS). These XAS data were fitted from linear combinations of spectra of well‐characterised Ru compounds. The absence of XAS data from the parent drugs in these fits points
抗转移药物NAMI‐A((ImH)[Ru III Cl 4(Im)(dmso)]; Im =咪唑,dmso = S键合的二甲基亚砜)和细胞毒性药物KP1019((IndH)[Ru III Cl 4(工业)2]; Ind = indazole)是人类临床试验中的两种基于Ru的抗癌药物。Ru K-edge X研究了它们在生物学相关条件下的反应性,包括水性缓冲液,蛋白质溶液或凝胶(例如白蛋白,转铁蛋白和胶原蛋白),未稀释的血清,细胞培养基和人肝(HepG2)癌细胞。射线吸收光谱法(XAS)。这些XAS数据来自特征明确的Ru化合物光谱的线性组合。在这些拟合中缺乏母体药物的XAS数据表明Ru III的协调环境发生了深刻变化。的拟合指向钌的存在IV / III簇和Ru的结合III到S-供体基团,蛋白质的胺/亚胺基和羧基基团。在相同条件下,KP1019的细胞吸收量约为NAMI-A的20倍,但在细胞培养基